1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Anemia – Pipeline Review, H1 2013

Anemia – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 119 pages

Anemia – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. Anemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anemia.
- A review of the Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Anemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Anemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Anemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Anemia - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anemia Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Anemia 9
Anemia Therapeutics under Development by Companies 11
Anemia Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Anemia Therapeutics - Products under Development by Companies 19
Anemia Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Anemia Therapeutics Development 22
Johnson and Johnson 22
Amgen Inc. 23
Eli Lilly and Company 24
Lentigen Corporation 25
Chong Kun Dang Pharmaceutical 26
Sandoz GmbH 27
Bayer AG 28
3SBio Inc. 29
Evotec Aktiengesellschaft 30
Ligand Pharmaceuticals Incorporated 31
PROLOR Biotech, Inc. 32
ReGenX Biosciences, LLC 33
ProMetic Life Sciences Inc. 34
Boryung Pharmaceutical Co., Ltd. 35
Green Cross Corporation 36
Asterion Ltd 37
Acceleron Pharma, Inc. 38
Pieris AG 39
Xenon Pharmaceuticals Inc. 40
Alder Biopharmaceuticals Inc. 41
Strativa Pharmaceuticals 42
NOXXON Pharma AG 43
Bolder Biotechnology, Inc. 44
Palkion, Inc. 45
Avesthagen Limited 46
PharmaEssentia Corporation 47
Anemia - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 54
darbepoetin alfa - Drug Profile 54
darbepoetin alfa - Drug Profile 56
sotatercept - Drug Profile 58
clazakizumab - Drug Profile 60
PRS-080 - Drug Profile 62
EPO Receptor Agonist - Drug Profile 64
PEGylated Erythropoietin - Drug Profile 65
ACE-536 - Drug Profile 66
PBI-1402 - Drug Profile 67
XEN-701 - Drug Profile 68
Drug For Anemia Of Inflammation - Drug Profile 69
HIF Stablilizer - Drug Profile 70
NOX-H-94 - Drug Profile 71
CNTO-530 - Drug Profile 73
erythropoietin biosimilar - Drug Profile 74
BR-05001 - Drug Profile 75
darbepoetin alfa - Drug Profile 76
Drug For Anemia - Drug Profile 77
epoetin alfa biosimilar - Drug Profile 78
LG-5640 - Drug Profile 80
PBI-4050 - Drug Profile 81
MOD-7023 - Drug Profile 82
epoetin alfa Long Acting - Drug Profile 84
LY-2928057 - Drug Profile 85
PBI-4494 - Drug Profile 86
BBT-021 - Drug Profile 87
BBT-009 - Drug Profile 88
cyanocobalamin - Drug Profile 89
BAY-85-3934 - Drug Profile 90
darbepoetin alfa - Drug Profile 92
salsalate - Drug Profile 93
TP-0413 - Drug Profile 94
Erythropoietin Biosimilar - Drug Profile 95
AFT-Erythropoietin - Drug Profile 96
Anemia Therapeutics - Drug Profile Updates 97
Anemia Therapeutics - Discontinued Products 105
Anemia Therapeutics - Dormant Products 106
Anemia - Product Development Milestones 108
Featured News and Press Releases 108
Appendix 116
Methodology 116
Coverage 116
Secondary Research 116
Primary Research 116
Expert Panel Validation 116
Contact Us 117
Disclaimer 117



List of Tables

Number of Products Under Development for Anemia, H1 2013 11
Products under Development for Anemia - Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2013 16
Comparative Analysis by Late Stage Development, H1 2013 17
Comparative Analysis by Mid Clinical Stage Development, H1 2013 18
Comparative Analysis by Early Clinical Stage Development, H1 2013 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Development by Companies, H1 2013 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2013 23
Johnson and Johnson, H1 2013 24
Amgen Inc., H1 2013 25
Eli Lilly and Company, H1 2013 26
Lentigen Corporation, H1 2013 27
Chong Kun Dang Pharmaceutical, H1 2013 28
Sandoz GmbH, H1 2013 29
Bayer AG, H1 2013 30
3SBio Inc., H1 2013 31
Evotec Aktiengesellschaft, H1 2013 32
Ligand Pharmaceuticals Incorporated, H1 2013 33
PROLOR Biotech, Inc., H1 2013 34
ReGenX Biosciences, LLC, H1 2013 35
ProMetic Life Sciences Inc., H1 2013 36
Boryung Pharmaceutical Co., Ltd., H1 2013 37
Green Cross Corporation, H1 2013 38
Asterion Ltd, H1 2013 39
Acceleron Pharma, Inc., H1 2013 40
Pieris AG, H1 2013 41
Xenon Pharmaceuticals Inc., H1 2013 42
Alder Biopharmaceuticals Inc., H1 2013 43
Strativa Pharmaceuticals, H1 2013 44
NOXXON Pharma AG, H1 2013 45
Bolder Biotechnology, Inc., H1 2013 46
Palkion, Inc., H1 2013 47
Avesthagen Limited, H1 2013 48
PharmaEssentia Corporation, H1 2013 49
Assessment by Monotherapy Products, H1 2013 50
Assessment by Stage and Route of Administration, H1 2013 52
Assessment by Stage and Molecule Type, H1 2013 55
Anemia Therapeutics - Drug Profile Updates 99
Anemia Therapeutics - Discontinued Products 107
Anemia Therapeutics - Dormant Products 108
Anemia Therapeutics - Dormant Products (Contd..1) 109



List of Figures

Number of Products under Development for Anemia, H1 2013 11
Products under Development for Anemia - Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 16
Late Stage Products, H1 2013 17
Mid Clinical Stage Products, H1 2013 18
Early Clinical Stage Products, H1 2013 19
Discovery and Pre-Clinical Stage Products, H1 2013 20
Assessment by Monotherapy Products, H1 2013 50
Assessment by Route of Administration, H1 2013 51
Assessment by Stage and Route of Administration, H1 2013 52
Assessment by Molecule Type, H1 2013 53
Assessment by Stage and Molecule Type, H1 2013 54

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Hemophilia Treatment Drugs Market: Overview Hemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary ...

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global apheresis market is projected to reach USD 2.06 billion by 2021, at a CAGR of 7.7% during the forecast period of 2016 to 2021. Growth in this market is majorly driven by the rising prevalence ...

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • December 2016
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Polycythemia Vera in 27 Major Markets Polycythemia Vera (PV), also known as erythraemia, erythrocytosis, erythrocytosis megalosplenica, ...


Download Unlimited Documents from Trusted Public Sources

Blood Disease Statistics in the US

  • February 2017
    24 pages
  • Blood Disease  

    Hospital  

    Intensive Care  

  • United States  

View report >

Blood Disease Statistics in the US

  • February 2017
    10 pages
  • Blood Disease  

    Blood Supply  

  • United States  

View report >

Blood Disease Statistics in the US

  • February 2017
    8 pages
  • Blood Disease  

    Cytokine  

    Cancer  

  • United States  

View report >

Related Market Segments :

Blood Disease

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.